Introduction
Interim ®ndings from the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT), and the withdrawal of the doxazosin treatment arm following reports of a higher incidence of certain types of cardiovascular disease (CVD), have received extensive coverage in the medical press over the past few months. This short communication aims to examine the reasons for the discontinuation of doxazosin from ALLHAT, and to clarify any issues around the use of alpha-1 adrenoceptor antagonists (alpha blockers), such as doxazosin, in the management of benign prostatic hyperplasia (BPH) in patients with and without hypertension.
Summary of the key preliminary ®ndings from the ALLHAT interim analysis
ALLHAT was designed to compare the effects of three newer classes of antihypertensive agents with diuretic (chlorthalidone) on the incidence of CVD in high-risk patients with hypertension 55 years and older. The representative new agents were: alpha blocker Ð doxazosin; calcium antagonist Ð amlodipine; and angiotensin converting enzyme (ACE) inhibitor Ð lisinopril. There was no placebo controls in the study.
The trial started in February 1994, and in January 2000 an independent data review committee recommended discontinuing the doxazosin treatment arm based on comparisons with chlorthalidone. Interim ®ndings, from a combined 24 335 patients in doxazosin and chlorthalidone groups, were presented in the Journal of the American Medical Association (JAMA) in April 2000, 1 and are summarized in Figure 1 and Table 1. In short, while there were no differences between the groups in the only composite primary endpoint of fatal coronary heart disease (CHD) or non-fatal myocardial infarction (MI), or in all-cause mortality, patients randomized to treatment with doxazosin had a higher incidence of combined CVD morbidity (P`0.001), driven by an approximate doubling in the risk of CHF with doxazosin relative to chlorthalidone (P`0.001). Combined CHD and stroke were also signi®cantly higher in the doxazosin treatment arm (P 0.05 and P 0.04, respectively). As the study was designed to test whether any of the three newer antihypertensive agents (amlodipine, doxazosin, or lisinopril) were superior in reducing cardiovascular outcomes compared with the established agent (chlorthalidone), there was little point in attempting to complete the doxazosin treatment arm. Had the doxazosin arm been continued, there was only an estimated 1% chance that doxazosin could be proven superior to chlorthalidone.
Interpretation of the ALLHAT interim data
While the data presented in JAMA are an important addition to the literature, we must remember that they are preliminary in nature, and many questions remain unanswered. What, for example, would we have expected from a placebo-control arm in ALLHAT? What impact does the`intention-to-treat' analysis have on the results? Were the doses of study drugs used appropriate? And, are these data in high-risk hypertensive patients of relevance to men with BPH?
Explaining the difference in CHF
Much of the post-JAMA debate and speculation has focused on the ®nding that patients treated with doxazosin were at almost twice the risk of congestive heart failure (CHF) compared to patients treated with chlorthalidone. True, the 4 y rates of CHF with doxazosin and chlorthalidone were 8.13% and 4.45%, respectively. But the comparison of the two agents cannot be considered in isolation. As there is no placebo control group in ALLHAT, it is not possible to determine whether the rate of CHF with doxazosin is the same, less, or more than would be expected in the absence of antihypertensive treatment. We can look to the results of other placebo-controlled trials, by way of reference. The Systolic Hypertension in the Elderly Program (SHEP) analysed the occurrence of major cardiovascular events (including CHF) in patients with isolated systolic hypertension who were taking diuretic or placebo. Following an average 4.5 y follow-up, fatal and non-fatal CHF rates were 2.3%
with chlorthalidone and 4.4% with placebo (P`0.001; Table 2 ). 2 The ratio of risk for chlorthalidone : placebo in SHEP (0.52) is not dissimilar to that of chlorthalidone : -doxazosin in ALLHAT (0.55), suggesting that doxazosin has a neutral effect with regard to CHF. In other words, CHF risk is not necessarily increased with doxazosin, but rather reduced by chlorthalidone. This is as we might expect, given that chlorthalidone is an approved treatment for CHF, whereas doxazosin is not.
Another point of interest is that if we look at the Kaplan ± Meier event plots for CHF, the doxazosin and chlorthalidone curves separate as early as the ®rst few months of follow-up (Figure 1 ). This early separation might be indicative of events related to discontinuation of prior antihypertensive therapy, rather than the effects of doxazosin per se, since CHF is unlikely to develop in such a short time period. The study design required that all patients discontinue any existing antihypertensive therapy at entry into ALLHAT. As 90% of patients were on antihypertensive treatment at the time, it is reasonable to assume that a proportion were taking either diuretics and/or ACE inhibitors, both of which could have been treating the symptoms of latent CHF. When treatment was withdrawn, and study drug initiated, these symptoms became apparent in the group no longer receiving therapy used to treat CHF, namely the doxazosin group. The precipitation of symptoms may have been exacerbated by the increase in plasma volume that can be seen with alpha blocker therapy.
How relevant are the respective blood pressures?
The very large sample size in ALLHAT allowed an almost identical distribution of baseline demographic characteristics in doxazosin and chlorthalidone treatment groups. However, patients in the doxazosin arm had a mean 2 ± 3 mmHg higher systolic blood pressure (SBP) throughout the treatment period, compared with patients treated with chlorthalidone (Figure 2 ). In the paper published in JAMA, the ALLHAT investigators speculate as to the clinical relevance of this, and suggest that a mean SBP 3 mmHg higher in the doxazosin group might account for some 10 ± 20% of the increase seen in CHF (calculations based on extrapolations of data from the SHEP and SystEur studies. 2, 3 In contrast, however, they conclude that most of the difference seen between doxazosin and chlorthalidone in the stroke and angina endpoints, could be a re¯ection of the different blood pressures in these two treatment groups.
The ALLHAT`intent to treat' analysis
Trials such as ALLHAT analyse results using an`intent to treat' patient population, ie the analysis includes all Table 2 Comparison of heart failure rates during follow-up of SHEP (4.5 y) and ALLHAT (4 y Implications from ALLHAT RS Kirby and JL Pool patients assigned to a particular study medication, irrespective of whether patients continued to take their medication as the trial progressed.`Intent to treat' is an established and accepted means of analysis that is intended to limit treatment bias. In this early analysis of ALLHAT, however, one limitation of this analytical method is a concern. By 4 y, at the point of this analysis, 14% of patients randomized to chlorthalidone had discontinued their assigned study drug, but 25% of doxazosin patients were no longer on their assigned medication. To fully understand how CVD and CHD events relate to study drug, and how these events relate to blood pressure control, an`on therapy' analysis is required. Poor adherence to therapy shouldn't necessarily be seen as a problem related to tolerability Ð it is fairly typical of large, simple studies that resemble clinical practice. Doxazosin and chlorthalidone were similarly tolerated in ALLHAT. At 4 y, 20% of patients had discontinued therapy because of adverse events in the chlorthalidone group, compared with 19% in the doxazosin group. Again, ALLHAT did not have a placebo arm, so a true appreciation of tolerability for either drug cannot be gained from the data. However, a number of studies have shown doxazosin to be well tolerated, in patients with hypertension, in patients with BPH, and in patients with concomitant disease. The Treatment of Mild Hypertension Study (TOMHS), which included both doxazosin and chlorthalidone as well as placebo, showed the general incidence of adverse events to be similar in both active treatment groups and with placebo. 4 The good tolerability pro®le of doxazosin extends across different age groups, 5 in short-and long-term studies, 6 ± 8 and is evident in both clinical trial and clinical practice settings. 4, 9, 10 What does this mean for the practising urologist?
In the current light of evidence, doxazosin remains an effective and well-tolerated agent as part of a multi-drug regimen in the management of hypertension and/or for symptomatic relief of BPH. We must remember that patients enrolled in ALLHAT had at least one other risk factor for CHD in addition to hypertension. They were a population at high risk of cardiovascular disease, in a trial designed to compare cardiovascular outcomes. ALLHAT did not study the use of doxazosin in the treatment of BPH. The investigators state that`the use of doxazosin as part of a multi-drug regimen for treating hypertension alone or hypertension and the symptoms of benign prostatic hypertrophy [sic] were not tested in this trial.' As such, ALLHAT offers little that is new for the urologist treating a patient with lower urinary tract symptoms, whether or not that patient has concomitant hypertension or is at risk of cardiovascular disease. Patients such as those studied in ALLHAT, as well as those seen in clinical practice, often require treatment with more than one antihypertensive agent to control their blood pressure. We should also remember that CHF is a disease state that all physicians, including urologists, should be aware of when older men present with BPH.
The role of doxazosin in the management of BPH has not changed, since it provides rapid and sustained symptomatic relief in most patients with BPH. As urologists, we should continue to treat patients with BPH as we have previously; if a patient develops heart failure, or if there are concerns about the potential development of heart failure, then that patient should be referred to a cardiovascular specialist. Analysis of the ALLHAT data is not yet complete, and further information is awaited with interest. Additional ALLHAT information will, however, be of questionable relevance to the patient with BPH, given the study design and objectives, patient population, and outcome measures that are already in place. 
